[Click eStock] "Qurient, Solution for Overcoming ADC Resistance"

On November 21, Daishin Securities expressed expectations that Qurient could address the unmet needs in the antibody-drug conjugate (ADC) market.

Lee Heeyoung, a researcher at Daishin Securities, explained, "Qurient has announced preclinical data for 'QP101,' a dual payload HER2 ADC that incorporates both a Topo-1 inhibitor and a CDK7 inhibitor into a single antibody, aiming to address the issue of 'Topo-1-based ADC resistance,' which is considered the largest unmet need after Enhertu. CDK7 is a key factor in DNA damage repair as well as transcription and cell cycle regulation."

He added, "The dual mechanism strategy involves the Topo-1 payload damaging the cancer cell DNA, while the CDK7 inhibitor simultaneously blocks DNA repair, fundamentally suppressing the tumor's survival capability."

He further emphasized, "The preclinical results demonstrated that the mechanistic design translated into actual efficacy. QP101 induced complete tumor regression even in Enhertu-resistant models, clearly overcoming the resistance limitations that single-payload Topo-1 ADCs could not address."

The researcher analyzed, "Even with the Topo-1 payload loaded at only about 25% of the level used in existing ADCs, QP101 showed equivalent or superior antitumor effects. Excellent tolerability was also confirmed in non-human primate (NHP) toxicity studies." He added, "QP101 is currently preparing for GLP toxicity studies and is being developed smoothly with the goal of submitting an Investigational New Drug (IND) application in 2027."

This content was produced with the assistance of AI translation services.